Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.

Humans Rifampin / adverse effects Antitubercular Agents / adverse effects Isoniazid / therapeutic use Drug Therapy, Combination Tuberculosis, Pulmonary / chemically induced

Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 8 2 2024
pubmed: 6 2 2024
entrez: 6 2 2024
Statut: ppublish

Résumé

High-Dose Rifampicin Regimen for Pulmonary TuberculosisThis randomized, controlled trial tested the efficacy and safety of high-dose rifampicin (1200 or 1800 mg/d) as part of the treatment regimen for pulmonary tuberculosis. Four-month high-dose rifampicin regimens had no dose-limiting side effects but failed to meet noninferiority criteria compared with the standard 6-month control regimen.

Identifiants

DOI: 10.1056/EVIDoa2300054 PMID: 38320155
pubmed: 38320155
doi: 10.1056/EVIDoa2300054
doi:

Substances chimiques

Rifampin VJT6J7R4TR
Antitubercular Agents 0
Isoniazid V83O1VOZ8L

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2300054

Subventions

Organisme : Medical Research Council
ID : MR/N006127/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V033417/1
Pays : United Kingdom

Auteurs

Amina Jindani (A)

Institute for Infection and Immunity, St. George's, University of London, London.

Daniel Atwine (D)

Epicentre/Mbarara Research Base, Mbarara, Uganda.
Mbarara University of Science and Technology, Mbarara, Uganda.

Daniel Grint (D)

London School of Hygiene and Tropical Medicine, London.

Boubacar Bah (B)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

Jack Adams (J)

Institute for Infection and Immunity, St. George's, University of London, London.

Eduardo Rómulo Ticona (ER)

Hospital Nacional Dos de Mayo, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Bhabana Shrestha (B)

German Nepal TB Project (GENETUP)/Nepal Anti TB Association (NATA), Kathmandu, Nepal.

Tefera Agizew (T)

University of Botswana, Gaborone, Botswana.

Saeed Hamid (S)

Aga Khan University Hospital, Karachi, Pakistan.

Bushra Jamil (B)

Aga Khan University Hospital, Karachi, Pakistan.

Adolf Byamukama (A)

Epicentre/Mbarara Research Base, Mbarara, Uganda.

Keneth Kananura (K)

Epicentre/Mbarara Research Base, Mbarara, Uganda.

Ivan Mugisha Taremwa (I)

Epicentre/Mbarara Research Base, Mbarara, Uganda.

Maryline Bonnet (M)

Epicentre/Mbarara Research Base, Mbarara, Uganda.
University of Montpellier, Recherche translationelles sur le virus de l'immunodéficience humaine et les maladies infectieuses, Institut de recherche pour le developpement, Institut national de la santé et de la recherche médicale, Montpellier, France.

Lansana Mady Camara (LM)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

Oumou Younoussa Bah-Sow (OY)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

Kindy Sadio Bah (KS)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

Nene Mamata Bah (NM)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

Maimouna Sow (M)

Centre Hospitalier Universitaire Ignace Deen, Conakry, Guinea.

César Eduardo Ticona Huaroto (CE)

Hospital Nacional Dos de Mayo, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Raquel Mugruza Pineda (R)

Hospital Nacional Dos de Mayo, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Bijesh Tandukar (B)

German Nepal TB Project (GENETUP)/Nepal Anti TB Association (NATA), Kathmandu, Nepal.

Bijendra Bhakta Raya (BB)

German Nepal TB Project (GENETUP)/Nepal Anti TB Association (NATA), Kathmandu, Nepal.

Neko Shrestha (N)

German Nepal TB Project (GENETUP)/Nepal Anti TB Association (NATA), Kathmandu, Nepal.

Anikie Mathoma (A)

University of Botswana, Gaborone, Botswana.

Unami P Mathebula-Modongo (UP)

University of Botswana, Gaborone, Botswana.

Joyce Basotli (J)

University of Botswana, Gaborone, Botswana.

Muhammad Irfan (M)

Aga Khan University Hospital, Karachi, Pakistan.

Dilshad Begum (D)

Aga Khan University Hospital, Karachi, Pakistan.

Ammara Muzammil (A)

Aga Khan University Hospital, Karachi, Pakistan.

Imran Ahmed (I)

Aga Khan University Hospital, Karachi, Pakistan.

Rumina Hasan (R)

Aga Khan University Hospital, Karachi, Pakistan.

Marcos V Burgos (MV)

Division of Infectious Diseases, University of New Mexico, Albuquerque, NM.

Faisal Sultan (F)

Shaukat Khanum Research Centre and Cancer Hospital, Lahore, Pakistan.

Mariam Hassan (M)

Shaukat Khanum Research Centre and Cancer Hospital, Lahore, Pakistan.

Iqra Masood (I)

Shaukat Khanum Research Centre and Cancer Hospital, Lahore, Pakistan.

Claire Robb (C)

Institute for Infection and Immunity, St. George's, University of London, London.

Jonathan Decker (J)

Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom.

Sisa Grubnic (S)

Clinical Academic Group in Infection and Immunity, St. George's University Hospitals National Health Service Foundation Trust, London.

Philip D Butcher (PD)

Institute for Infection and Immunity, St. George's, University of London, London.

Adam Witney (A)

Institute for Infection and Immunity, St. George's, University of London, London.

Jasvir Dhillon (J)

Institute for Infection and Immunity, St. George's, University of London, London.

Tulika Munshi (T)

Institute for Infection and Immunity, St. George's, University of London, London.

Katherine Fielding (K)

London School of Hygiene and Tropical Medicine, London.

Thomas S Harrison (TS)

Institute for Infection and Immunity, St. George's, University of London, London.
Clinical Academic Group in Infection and Immunity, St. George's University Hospitals National Health Service Foundation Trust, London.
Medical Reserach Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Four-Month High-Dose Rifampicin Regimens for...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifampicine › Four-Month High-Dose Rifampicin Regimens for...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Antituberculeux › Four-Month High-Dose Rifampicin Regimens for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides isonicotiniques › Isoniazide › Four-Month High-Dose Rifampicin Regimens for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Four-Month High-Dose Rifampicin Regimens for...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Tuberculose pulmonaire › Four-Month High-Dose Rifampicin Regimens for...